China SXT Pharmaceuticals, Inc.
SXTC
$2.86
$0.3714.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -11.73% | -11.73% | 29.55% | 29.55% | -22.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.73% | -11.73% | 29.55% | 29.55% | -22.23% |
| Cost of Revenue | 6.70% | 6.70% | 69.45% | 69.45% | -41.78% |
| Gross Profit | -53.26% | -53.26% | -21.09% | -21.09% | 221.88% |
| SG&A Expenses | -91.98% | -91.98% | -257.31% | -257.31% | 677.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.73% | -85.73% | -228.68% | -228.68% | 336.18% |
| Operating Income | 93.17% | 93.17% | 276.67% | 276.67% | -712.67% |
| Income Before Tax | 91.72% | 91.72% | 248.59% | 248.59% | -548.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 91.72% | 91.72% | 248.59% | 248.59% | -548.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 91.72% | 91.72% | 248.59% | 248.59% | -548.75% |
| EBIT | 93.17% | 93.17% | 276.67% | 276.67% | -712.67% |
| EBITDA | 93.84% | 93.84% | 285.44% | 285.44% | -788.72% |
| EPS Basic | 98.72% | 98.72% | 152.00% | 152.00% | -32.37% |
| Normalized Basic EPS | 98.72% | 98.72% | 160.06% | 160.06% | -32.37% |
| EPS Diluted | 98.72% | 98.72% | 152.00% | 152.00% | -32.37% |
| Normalized Diluted EPS | 98.72% | 98.72% | 160.06% | 160.06% | -32.37% |
| Average Basic Shares Outstanding | 544.18% | 544.18% | 185.56% | 185.56% | 389.84% |
| Average Diluted Shares Outstanding | 544.18% | 544.18% | 185.56% | 185.56% | 389.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
